The Trump administration's proposed 100% tariffs on pharmaceutical imports, announced under Section 232 of the Trade Expansion Act, have sent shockwaves through India's pharmaceutical sector. But here's the thing: this isn't a blanket blow to everyone. The policy creates a divergent landscape where generics—comprising 88% of India's $10.5 billion pharma exports to the US—remain temporarily exempt, while branded and specialty drugs face direct impact . The latest announcement on April 2, 2026, specifically targets drugmakers without low-price agreements, with potential tariffs ranging from 100% to 200% .
This isn't just another trade dispute. The convergence of tariff measures and enhanced US FDA regulatory scrutiny creates a complex dual-pressure environment that could fundamentally reshape the global pharmaceutical supply chain. Let's break down what this means for three major Indian players and how they're navigating this new reality.
Biocon: The Bullseye with a Shield
Biocon finds itself in the toughest spot among the three. With 46.1% of revenue coming from the US market, primarily through branded biosimilars, the company faces direct tariff exposure AnnualReports. Its key products—Fulphila® (25% US market share), Ogivri® (23%), and Semglee® (10%)—fall squarely under the branded/patented drug category subject to tariffs AnnualReports. The market reacted swiftly, with Biocon's stock dropping 5.46% on the news, the steepest decline among the three companies.
The margin compression risk is real. Biocon's North America segment delivers a healthy 28% EBITDA margin, but a 100% tariff could significantly compress these margins InvestorPresentations. The company's biologics portfolio, while differentiated, still faces constraints in passing tariff costs to US payors due to rebate structures and regulatory price controls.
However, Biocon has a significant ace up its sleeve: US manufacturing presence. The company operates five manufacturing locations including facilities in New Jersey and Maryland InvestorPresentations +1. Companies with pharmaceutical manufacturing plants "under construction" or operational in the US are exempt from the 100% tariffs . The Cranbury facility in New Jersey is already FDA-qualified for three vertically integrated statin products, with commercial supplies commenced and a five-year national contract secured AnnualReports. The Bayview facility in Maryland is undergoing validation for monoclonal antibodies AnnualReports.
This manufacturing footprint, combined with strong regulatory compliance (zero FDA warning letters in FY25 and VAI classifications across all facilities), provides a critical mitigation pathway AnnualReports. Biocon's biologics portfolio also demonstrates superior pricing power compared to generic formulations, with 25-31% segment margins providing a buffer against tariff pressure InvestorPresentations +1. The company's ability to pass through 35-50% of tariff costs versus generic manufacturers' 15-30% reflects the pricing power of differentiated biologics.
Aurobindo Pharma: High Exposure, Temporary Buffer
Aurobindo Pharma presents a fascinating case study in risk and resilience. The company derives 45.6% of its revenue from the US market AnnualReports, creating significant concentration risk. Yet its stock declined only 3.58%—the mildest reaction among the three. Why? Because Aurobindo's portfolio is predominantly generic, and generics are currently exempt from the 100% tariffs .
But this buffer comes with a major caveat. The Section 232 investigation could expand tariffs to include generics and APIs, which would directly impact Aurobindo's core business . The company is already facing pricing pressure in the US generics market, with management offering "discounts to customers for benchmarking and competing with competitor pricing" AnnualReports. The US generic market is described as "the most dynamic and competitive generic drug market globally" AnnualReports, severely constraining Aurobindo's ability to pass tariff costs to payors.
If tariffs expand to generics, Aurobindo's 58.9% gross margin could face erosion of 15-25 percentage points, assuming limited price pass-through InvestorPresentations. The company's EBITDA margin of ~20% and net profit margin of ~11% would face significant pressure under such scenarios InvestorPresentations +1. Even with 52% backward integration, Aurobindo remains dependent on imported APIs for 48% of requirements, and tariffs on APIs would further compress margins AnnualReports.
Aurobindo is accelerating its US manufacturing expansion with facilities in Carolina, Dayton, and Raleigh to secure tariff-exempt production capacity AnnualReports. The company is also evaluating USMCA-qualified manufacturing in Mexico, which offers 0% duty-free entry for qualifying goods, though this comes with significant complexity including Regional Value Content thresholds of 60% . Additionally, Aurobindo is enhancing backward integration—currently at 52%—to reduce dependency on imported APIs, 44% of which come from China AnnualReports +1.
Glenmark: The Strategic Pivot
Glenmark Pharmaceuticals tells a different story. With only 22.7% of consolidated revenue from North America (FY25), the company has the lowest direct US exposure among the three AnnualReports. Yet its stock declined 4.68%, exceeding Aurobindo's drop. This disproportionate reaction suggests market concerns beyond just US revenue exposure, potentially related to revenue concentration risk and a slowing US market forecast of only 3-6% CAGR over the next five years (down from 6.8%) AnnualReports.
Glenmark is executing a strategic pivot toward domestic and non-US markets. India business grew 22.1% in Q3 FY26, with the company ranked 2nd in Dermatology, 2nd in Respiratory, and 4th in Cardiac segments InvestorPresentations. The company is targeting over 70% revenue from branded markets by FY 2030 (currently >60%) AnnualReports. This strategic transformation is already underway, with innovative launches including the world's first nebulized fixed-dose triple therapy for COPD (NEBZMART® GFB Smartules®) and strong growth in the oncology portfolio InvestorPresentations.
Geographic diversification is gathering momentum. Europe grew 9.1% in Q3 FY26, while emerging markets delivered 8.4% growth InvestorPresentations. The RYALTRIS® product is expanding across 90+ countries, with marketing applications submitted in more than 90 markets and commercialized in 52 as of December 2025 InvestorPresentations. China approval was secured in October 2025, with launch expected in Q1 FY27, while Thailand partner Organon is preparing for Q4 FY26 launch InvestorPresentations.
Glenmark has implemented comprehensive cost efficiency measures, but these have natural limits. The company achieved significant margin improvement with EBITDA margin reaching 22.3% in Q3 FY26, up from 10.1% in FY 2024 AnnualReports +1. However, most major efficiency gains have already been captured, and further reductions would require significant capital investment that may not generate adequate ROI under tariff pressure.
The Regulatory Wildcard
The tariff situation is complicated by enhanced US FDA scrutiny. The FDA's PreCheck Initiative creates regulatory advantages for US-based facilities through early engagement, predictable regulatory pathways, and accelerated time-to-market . Foreign facilities continue to face traditional inspection processes with higher uncertainty and longer timelines. This regulatory advantage compounds the tariff exemption benefits for companies with US manufacturing presence.
Unannounced inspections are expanding, with the FDA's New Delhi office enabling the agency to "ramp up inspections more quickly than elsewhere—making Indian manufacturers potentially an early focal point" . Previous surprise inspection pilots resulted in "increased import alerts, warning letters, and delayed approvals for noncompliant facilities in India and China" . Indian manufacturers are advised to "conduct surprise mock inspections and establish continuous inspection readiness—assume the FDA may arrive unannounced at any time" .
What Lies Ahead
The market is pricing in a 40-65% probability of permanent tariff impact across these companies, with valuation multiples reflecting moderate-to-severe but not catastrophic scenarios. Current valuation multiples suggest investors are assigning varying degrees of confidence: Aurobindo at 40-50% probability of permanent tariffs, Biocon at 55-65%, and Glenmark at 30-40%.
Historical precedents from the 2018-2019 US-China trade war show that while short-term volatility is likely, recovery typically occurs within 6-12 months of resolution. However, the current situation differs in scale and specificity. The 100% tariff proposal is significantly larger than the 25% tariffs in 2018-2019, and the direct targeting of pharmaceuticals combined with enhanced regulatory scrutiny creates a more complex challenge.
For investors, the key is differentiation. Biocon's US manufacturing presence provides tariff exemption but its branded portfolio faces direct impact. Aurobindo's generic focus offers temporary protection but carries expansion risk. Glenmark's geographic diversification and strategic pivot toward branded markets offer natural hedges, though limited US manufacturing reduces tariff exemption options.
The next 12-24 months will be critical. Companies that accelerate US manufacturing investments, transform their product portfolios toward complex generics and specialty products, and successfully diversify geographically will emerge stronger. Those that don't may face structural decline in their most important market. The convergence of trade barriers and regulatory requirements is creating a transformative challenge that could reshape the global pharmaceutical supply chain for years to come.
